Estados financieros detallados de IDEAYA Biosciences, Inc. (IDYA): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
IDEAYA Biosciences, Inc. registró ingresos de $218.7M en el último ejercicio fiscal, con un CAGR de 5 años del 62.1%.
Márgenes de los últimos 12 meses: margen bruto -13.3%, margen operativo -92.7%, margen neto -74.8%.
Al precio actual de $37.73, IDYA presenta beneficios negativos (P/E no significativo) y un ROE del -16.47%. La capitalización bursátil es de $3.6B.
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | $19.5M | $27.9M | $50.9M | $23.4M | $7.0M | $218.7M |
| Coste de Ventas | $391000 | $886000 | $1.2M | $1.4M | $1.7M | $2.1M | $4.0M | $3.8M | $314.7M |
| Beneficio Bruto | -$391000 | -$886000 | -$1.2M | $18.2M | $26.2M | $48.8M | $19.4M | $3.2M | -$96.0M |
| I+D | $12.4M | $31.7M | $34.3M | $39.7M | $58.2M | $89.5M | $129.5M | $294.7M | $314.7M |
| Generales y Administrativos | $1.7M | $3.8M | $8.7M | $13.8M | $18.3M | $21.8M | $24.3M | $35.5M | $63.3M |
| Gastos Operativos | $14.0M | $35.5M | $43.0M | $53.5M | $76.5M | $111.3M | $153.8M | $330.1M | $63.3M |
| Beneficio Operativo | -$14.4M | -$36.4M | -$44.3M | -$35.3M | -$50.3M | -$62.5M | -$134.4M | -$327.0M | -$159.3M |
| EBITDA | -$11.5M | -$33.5M | -$40.7M | -$33.1M | -$48.0M | -$56.6M | -$109.0M | -$270.6M | -$154.7M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$11.9M | -$34.3M | -$42.0M | -$34.5M | -$49.8M | -$58.7M | -$113.0M | -$274.5M | -$113.7M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$11.9M | -$34.3M | -$42.0M | -$34.5M | -$49.8M | -$58.7M | -$113.0M | -$274.5M | -$113.7M |
| BPA | $-0.83 | $-2.41 | $-1.90 | $-1.31 | $-1.41 | $-1.42 | $-1.96 | $-3.36 | $-1.28 |
| BPA Diluido | $-0.83 | $-2.41 | $-1.90 | $-1.31 | $-1.41 | $-1.42 | $-1.96 | $-3.36 | $-1.28 |
| Acciones en Circulación (Diluidas) | $14.2M | $14.2M | $20.2M | $24.7M | $35.3M | $41.4M | $57.5M | $81.7M | $88.5M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | $207.8M | $10.9M | $6.6M | $8.9M |
| Beneficio Bruto | $124.8M | -$75.7M | -$89.2M | $8.9M |
| Beneficio Operativo | $108.5M | -$94.6M | -$108.5M | -$122.3M |
| EBITDA | $109.5M | -$93.4M | -$107.4M | -$121.2M |
| Beneficio Neto | $119.2M | -$83.3M | -$98.5M | -$112.5M |
| BPA | $1.35 | $-0.94 | $-1.11 | $-1.22 |
| BPA Diluido | $1.33 | $-0.94 | $-1.11 | $-1.22 |
Balance (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $6.0M | $20.5M | $34.1M | $72.0M | $92.0M | $68.6M | $157.0M | $84.4M | $112.8M |
| Inversiones a Corto | $7.2M | $69.5M | $64.9M | $211.5M | $154.7M | $296.2M | $368.1M | $591.9M | $526.6M |
| Cuentas por Cobrar | 0 | 0 | 0 | $1.9M | $1.1M | $211000 | $18000 | $3000 | $6.0M |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $13.6M | $90.7M | $101.7M | $288.6M | $251.0M | $370.5M | $532.6M | $689.7M | $666.7M |
| Inmovilizado Material | $3.7M | $5.2M | $9.7M | $9.5M | $8.7M | $9.0M | $8.4M | $27.7M | $31.3M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $17.5M | $96.5M | $113.0M | $298.3M | $381.3M | $388.0M | $649.3M | $1.12B | $1.11B |
| Cuentas por Pagar | $662000 | $1.4M | $709000 | $953000 | $2.1M | $4.3M | $6.6M | $15.4M | $17.6M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $339000 |
| Pasivos Corrientes | $2.4M | $5.4M | $6.9M | $38.6M | $45.2M | $31.7M | $27.1M | $46.1M | $58.8M |
| Deuda a Largo | $3.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $27.6M |
| Pasivos Totales | $33.2M | $145.5M | $12.6M | $100.0M | $79.8M | $38.5M | $28.2M | $64.9M | $86.4M |
| Reservas | -$16.2M | -$50.5M | -$92.5M | -$127.0M | -$176.7M | -$235.4M | -$348.4M | -$622.8M | -$736.5M |
| Patrimonio Neto | -$15.7M | -$48.9M | $100.4M | $198.3M | $301.5M | $349.5M | $621.1M | $1.06B | $1.02B |
| Deuda Total | $3.2M | 0 | $6.8M | $6.7M | $5.2M | $3.5M | $2.9M | $19.2M | $27.9M |
| Deuda Neta | -$9.9M | -$90.0M | -$92.2M | -$276.9M | -$241.6M | -$361.3M | -$522.2M | -$657.1M | -$611.5M |
| Capital Circulante | $11.1M | $85.3M | $94.7M | $250.0M | $205.8M | $338.7M | $505.5M | $643.6M | $607.9M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $298.9M | $112.8M | $157.5M | $272.6M |
| Activos Totales | $1.19B | $1.11B | $1.03B | $1.31B |
| Pasivos Totales | $93.1M | $86.4M | $93.1M | $110.8M |
| Patrimonio Neto | $1.09B | $1.02B | $937.3M | $1.20B |
| Deuda Total | $27.2M | $55.5M | $28.6M | $29.3M |
Flujo de Caja (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$11.9M | -$34.3M | -$42.0M | -$34.5M | -$49.8M | -$58.7M | -$113.0M | -$274.5M | -$113.7M |
| Amortizaciones | $391000 | $886000 | $1.2M | $1.4M | $1.7M | $2.1M | $4.0M | $3.8M | $4.6M |
| Compensación en Acciones | $136000 | $950000 | $2.2M | $3.6M | $8.2M | $11.6M | $18.5M | $34.7M | $46.1M |
| Cambio en Capital Circulante | $1.6M | $1.7M | -$284000 | $84.4M | -$17.8M | -$41.6M | -$13.2M | $11.5M | $1.9M |
| Flujo de Caja Operativo | -$12.2M | -$27.6M | -$39.3M | $55.5M | -$55.8M | -$87.2M | -$115.2M | -$247.6M | -$71.1M |
| Inversiones (CapEx) | -$1.8M | -$1.7M | -$1.4M | -$493000 | -$2.6M | -$3.4M | -$2.4M | -$3.9M | -$2.4M |
| Adquisiciones | 0 | 0 | -$8000 | -$18000 | $67.0M | $33.4M | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$14.0M | -$29.3M | -$40.7M | $55.0M | -$58.4M | -$90.6M | -$117.6M | -$251.4M | -$73.5M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | $142.2M | -$90.5M | -$75.2M | -$163.4M |
| Inversiones (CapEx) | -$42000 | -$333000 | -$967000 | -$1.8M |
| Flujo de Caja Libre | $142.2M | -$90.8M | -$76.1M | -$165.2M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $12.2M | $11.8M | $14.5M | $31.2M |
Crecimiento y Márgenes (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | | | | +43.0% | +82.3% | -54.1% | -70.1% | +3024.4% |
| Crecimiento Beneficio Neto (anual) | | -189.5% | -22.2% | +17.8% | -44.3% | -17.9% | -92.6% | -143.0% | +58.6% |
| Crecimiento BPA (anual) | | -190.4% | +21.2% | +31.1% | -7.6% | -0.7% | -38.0% | -71.4% | +61.9% |
| Cambio en Acciones (anual) | | +0.0% | +42.1% | +22.2% | +42.6% | +17.6% | +38.8% | +42.0% | +8.3% |
| Crecimiento FCF (anual) | | -109.8% | -38.7% | +235.2% | -206.3% | -55.1% | -29.8% | -113.8% | +70.8% |
| Margen Bruto | | | | 92.9% | 93.8% | 95.9% | 82.9% | 45.2% | -43.9% |
| Margen Operativo | | | | -180.9% | -179.9% | -122.7% | -574.9% | -4671.1% | -72.8% |
| Margen EBITDA | | | | -169.5% | -171.9% | -111.0% | -465.9% | -3866.3% | -70.7% |
| Margen Neto | | | | -176.6% | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| Margen FCF | | | | 281.3% | -209.1% | -177.9% | -502.9% | -3592.0% | -33.6% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-0.98 | $-2.06 | $-2.01 | $2.22 | $-1.66 | $-2.19 | $-2.04 | $-3.08 | $-0.83 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $14.2M | $14.2M | $20.2M | $24.7M | $35.3M | $41.4M | $57.5M | $81.7M | $88.5M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -16.47% |
| Rentabilidad sobre capital invertido | -17.66% |
| Rentabilidad sobre activos | -13.36% |
| Margen bruto | -13.32% |
| Margen operativo | -92.66% |
| Margen neto | -74.75% |
Salud financiera
| Deuda / Patrimonio | 0.02 |
| Ratio corriente | 10.45 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 20.70 |
Ratios Clave (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -13.48 | -4.64 | -3.95 | -10.69 | -16.77 | -12.80 | -18.15 | -7.65 | -27.01 |
| P/VC | -10.12 | -3.26 | 1.51 | 1.75 | 2.76 | 2.15 | 3.30 | 1.98 | 2.99 |
| P/V | 0.00 | 0.00 | 0.00 | 17.71 | 29.83 | 14.79 | 87.52 | 299.88 | 13.99 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 92.9% | 93.8% | 95.9% | 82.9% | 45.2% | -43.9% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | -180.9% | -179.9% | -122.7% | -574.9% | -4671.1% | -72.8% |
| Margen Neto | 0.0% | 0.0% | 0.0% | -176.6% | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |